None listed
Conditions
Brief summary
The Younger Women's Wellness after Cancer Program (YWWACP) will determine the effect of a 12 week, e-health enabled program, on the health-related quality of life (HRQoL) in women who have received treatment for breast or gynaecological cancer. Who is it for? You may be eligible to join this study if you are a female aged between 20-40 years who has completed surgery, chemotherapy and/or radiotherapy within the past 12 months for early or local breast and/or gynaecological cancer. Study details Participants in this study are randomly allocated (by chance) to one of two groups. Participants in the intervention group are given access to an e-health enabled, structured health promotion program which will include an interactive iBook and website containing health information, planning and goal setting, and three personal conferences with a nurse via video-conferencing over 12 weeks. Participants in the control group will receive usual care which includes only that information and support that is given as part of usual practice through their usual clinic visits. Participants from both groups will be asked to complete questionnaires before the program begins (0 weeks), at 12 weeks, and again at 24 weeks, in order to determine the effect of the program on HRQoL, dietary intake, physical activity levels, sleep quality, levels of stress, anxiety and depression, menopausal symptoms, and sexual function. They will also have their height, weight and other anthropometric measures taken at these timepoints.
Interventions
The intervention is a 12 week, e-health enabled, structured health promotion intervention targeted at improving health related quality of life and reducing chronic disease risk factors in women between 20 and 50 years of age who have previously been treated for breast, haematological and gynaecological cancers. All women in the intervention arm will receive health education material, including a Program Journal (in the form of an interactive iBook), and access to an interactive web interface. Th
The intervention is a 12 week, e-health enabled, structured health promotion intervention targeted at improving health related quality of life and reducing chronic disease risk factors in women between 20 and 50 years of age who have previously been treated for breast, haematological and gynaecological cancers. All women in the intervention arm will receive health education material, including a Program Journal (in the form of an interactive iBook), and access to an interactive web interface. The iBook includes sections on healthy eating, sleep, exercise advice, tips for managing fatigue and stress, mindfulness, and will encourage women to bring together these various components of the health education provided and incorporate them into their lives over a 12-week period. The iBook includes a weekly exercise planner, where women are encouraged to use this journal daily and to plan ahead for their exercise in the following week. Participants will receive access to self-directed resources (via the website) and personal consultations (via videoconference) with a nurse. Three individual, virtual 30 minute consultations at 0, 6 and 12 weeks will be provided by a registered nurse trained in the intervention.
Sponsors
Queensland University of Technology
Study design
Allocation
Randomised controlled trial
Intervention model
Parallel
Primary purpose
Educational / counselling / training
Masking
Blinded (masking used) (Subject, Caregiver, Investigator, Outcomes Assessor)
Eligibility
Sex/Gender
All
Age
20 Years to 50 Years
Healthy volunteers
No
Inclusion criteria
(1) Completed surgery or chemotherapy (primary or adjuvant) and/or radiotherapy for blood, breast and/or gynaecological cancer (2) Able to speak and read Level 10 English (3) Must have access to internet (4) not currently receiving any cytotoxic maintenance treatments
Exclusion criteria
(1) Metastatic or advanced cancer and inoperable or active loco-regional disease (2) Any clinical, cognitive or psychiatric contraindication identified by treating staff (3) Participants on cytotoxic maintenance treatments will be excluded
Outcome results
None listed